Introduction {#S1}
============

Spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive neurodegenerative disorders with obvious clinical and genetic heterogeneity ([@B68]). To date, more than 40 genetically distinct SCA subtypes have been identified ([@B68]). Spinocerebellar ataxia type 3, also known as Machado--Joseph disease (SCA3/MJD), is the most common type of autosomal dominantly inherited cerebellar ataxia ([@B138]; [@B60]; [@B24]; [@B20]). The characterized manifestations include not only progressive cerebellar ataxia but also pyramidal and extrapyramidal signs, such as dysarthria, dysphagia, dystonia, peripheral neuropathy, and oculomotor abnormalities ([@B124]; [@B24]). SCA3/MJD is caused by unstable cytosine--adenine--guanine (CAG) repeats located in the 10th exon of the ATXN3 gene ([@B64]; [@B124]; [@B19]). The number of repeats in the mutant ATXN3 allele ranges from 52 to 91 in SCA3/MJD patients, which results in the expansion of a polyglutamine tract within the ATXN3 protein ([@B140]; [@B133]). The accumulation and the aggregation of expanded polyglutamine stretches within the nuclei of neurons in susceptible brain regions might induce direct or indirect neurotoxic effects that eventually lead to neuron loss and brain atrophy ([@B153]; [@B24]). These abnormalities in neuronal nuclei involve both cortical and subcortical regions, including the cerebral cortex, basal ganglia, thalamus, cerebellum, and brain stem, as observed in previous neuropathological and histopathological studies ([@B38]; [@B153]; [@B124]). These brain lesions may be responsible for the motor and the mental dysfunctions identified in SCA3/MJD patients in previous clinical and neuroradiological studies ([@B68]; [Figure 1](#F1){ref-type="fig"}). The earliest pathophysiological changes precede the appearance of ataxia symptoms in preclinical SCA carriers ([@B84]), and detailed knowledge of the preclinical stage is of great significance for a more comprehensive understanding of the pathogenesis of SCAs. Two primary scales currently used to quantify the motor defects of ataxia in natural history studies of SCAs are the Scale for the Assessment and Rating of Ataxia (SARA) ([@B123]) and the International Cooperative Ataxia Rating Scale (ICARS) ([@B142]), both of which are semi-quantitative and have been extensively validated as useful tools for ataxia severity assessment ([@B28]); the higher the total score, the worse is the patient's ataxic syndrome. In addition, the total score has been shown to be correlated with measures of the quality of life in patients with SCAs ([@B118]). However, these scales lack sensitivity in the early stages of SCA, including in the preclinical stages when disease-modifying therapies and neuroprotective agents are likely to be most effective ([@B117]), and usually have poor test--retest reliability ([@B92]). Consequently, non-invasive and objective biomarkers should supplement clinical scales to directly identify subtle brain abnormalities in individuals before the onset of ataxia and assess the treatment effects of therapeutic interventions. Neuroimaging techniques have shown promising results in the investigation of brain damage with high accuracy and reproducibility. Since SCAs have extremely low prevalence rates ([@B126]) and histopathological data are scarcely available for most degenerative ataxias, magnetic resonance (MR)-based structural and functional imaging techniques have gained growing attention in the exploration of pathogenic mechanisms and potential biomarkers that can indicate disease progression even in the preclinical stage of neurodegenerative diseases such as SCA ([@B35]; [@B29]; [@B8]; [@B87]). Structural or functional abnormalities of the brain tissue can be observed by different MR imaging techniques, including morphometric magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), blood oxygen level-dependent functional MRI (BOLD fMRI), and magnetic resonance spectroscopy (MRS). The utility of these techniques constitutes a potential source of neuroimaging biomarkers, which can be used to identify potential pathogenesis underlying both manifested and preclinical SCA patients, assess disease severity and progression, monitor therapeutic effects, and determine nuances that can be used as endpoints for future clinical trials. Given this scenario, the purpose of this review was to summarize the main MR imaging properties and their correlation with clinical features in manifested and preclinical SCA3/MJD patients, which could help to assess the value of MR imaging indicators as diagnostic, disease progression, and surrogate biomarkers for SCA3/MJD.

![The pathological mechanisms underlying atrophy and its correlations with clinical manifestations.](fnins-14-00749-g001){#F1}

Morphometric MRI {#S2}
================

Morphometric MRI has become a standard method to monitor brain morphological alterations in neurodegenerative diseases. In patients with SCAs, the main focus has been the visualization and the quantification of brain volume changes that particularly affect the cerebellum and the brainstem. Patterns of atrophy in different SCA genotypes are specific but sometimes overlapping. Voxel-based morphometry (VBM) allows a quantitative assessment and automatic unbiased measurement of brain tissue density and volume with high accuracy and repeatability.

Widespread Alterations in Brain Morphology in SCA3/MJD Patients {#S2.SS1}
---------------------------------------------------------------

Previous conventional MRI study using manual segmentation method has revealed widespread lesions in the brain structure of SCA3/MJD patients, including those in the cerebellum, brain stem, cerebral cortex, and basal ganglia ([@B69]). Morphometric MRI studies using VBM analysis allow a quantitative and automatic assessment of brain atrophy in the cerebellum, brainstem, basal ganglia, thalamus, and distinct cortical areas, as shown in [Figure 2](#F2){ref-type="fig"} and summarized in [Table 1](#T1){ref-type="table"}. Widespread reductions in cortical gray matter density validated the atrophy of the whole brain ([@B30]). To quantify the shape complexity of cortical folding, three-dimensional fractal dimension method was applied in the assessment of cortical degeneration, and reduced cerebral complexity more extensive than traditional olivopontocerebellar regions and the corticocerebellar system was detected ([@B148]; [@B147]; [@B54]). Besides that, the involved cortex widely overlaps with cerebellum-related cortex and basal ganglia-related cortex ([@B147]). Using volumetric measurements, SCA3/MJD patients showed extensive atrophy of the cerebral cortex, thalamus, and basal ganglia, as well as the cerebellum and the brainstem ([@B112]). The cerebellum and the brainstem, compared with the other abovementioned regions, appear to be more severely affected in SCA3/MJD patients ([@B83]; [@B126]; [@B39]; [@B63]; [@B50]; [@B112]; [@B104]). Susceptibility-weighted imaging revealed atrophy of the cerebellar nuclei in SCA3/MJD patients ([@B134]), and a hyperintense signal of the transverse pontine fibers was observed by T2-weighted and/or proton-weighted axial MRI in 14 out of 31 SCA3 patients ([@B93]) as well as in one other postmortem-confirmed case ([@B55]), which are all consistent with an olivopontocerebellar atrophy pattern as demonstrated in neuropathologic studies ([@B38]; [@B124]).

###### 

Summary of baseline data of the affected brain regions detected with voxel-based morphometry analysis.

  References   Sample size   Age     AOO     DD      CAG     Ataxia scale                                            Ataxia score   MRI scanner                     Magnetic flux density   Head coil    Cere- bellum   Brain stem   Cere- brum   Basal ganglia   Thalami   Limbic system
  ------------ ------------- ------- ------- ------- ------- ------------------------------------------------------- -------------- ------------------------------- ----------------------- ------------ -------------- ------------ ------------ --------------- --------- ---------------
  [@B104]      31            38.91   34.88   4.81    71.84   International Cooperative Ataxia Rating Scale (ICARS)   26.81          Sonata, Siemens                 1.5 T                   --           √              √            √                                      √
  [@B88]       17            45.3    35.6    9.7     70      Scale for the Assessment and Rating of Ataxia (SARA)    10             Achieva, Philips                3 T                     32-channel   √                           √            √                         
  [@B50]       17            40.41   33.47   6.94    \-      SARA                                                    13.26          Achieva, Philips                3 T                     32-channel   √              √            √                                      
  [@B37]       13            43.66   32.94   7.51    65.67   SARA                                                    11.92          Magnetom TIM Trio, Siemens      3 T                     12-channel   √              √            √                            √         √
  [@B63]       12            50.5    --      11.0    70.6    SARA                                                    10.3           Magnetom TIM Trio, Siemens      3 T                     8-channel    √              √                                         √         
  [@B49]       38            40.38   40.02   9.3     68.08   ICARS/SARA                                              32.08/14.65    Achieva, Philips                3 T                     --           √              √                                                   
  [@B82]       32            46.78   36.72   10.09   69.0    SARA                                                    13.6           Achieva, Philips                3 T                     --           √                           √            √                         √
  [@B30]       45            47.02   37.04   9.97    72      ICARS                                                   36.36          Elscint Prestige                2 T                     --           √              √            √            √               √         √
  [@B47]       10            38.0    \-      5.8     --      ICARS                                                   48.6           Magnetom Vision Plus, Siemens   1.5 T                   --           √                           √                                      √
  [@B126]      24            47.3    \-      11.7    --      SARA                                                    12.0           Sonata, Siemens                 1.5 T                   --           √              √                                                   
  [@B95]       4             73      \-      12      --      --                                                      --             Magnetom Symphony, Siemens      1.5 T                   --           √              √                                                   
  [@B83]       9             53      47      --      64      ICARS                                                   30             Magnetom Symphony, Siemens      1.5 T                   --           √              √            √                                      

AOO, age of onset; DD, disease duration.

![Areas of decreased gray matter density (hot colors) and white matter density (cold colors) when comparing MJD/SCA3 and controls (*P* \< 0.001). Reprinted with permission from Wiley ([@B30]).](fnins-14-00749-g002){#F2}

Volume reductions in the basal ganglia area of SCA3/MJD patients have also been reported ([@B69]; [@B93]; [@B33]; [@B112]). Pallidal atrophy was found in two patients whose disease durations were over 10 years ([@B141]), and significant decreases in gray matter volume were observed in the putamen and the pallidum ([@B82]; [@B110]). Some studies have failed to observe atrophy of the basal ganglia, which might be attributable to the relatively short disease duration of the recruited patients ([@B104]).

In order to find out whether cerebral cortex is affected in SCA3/MJD patients and to find the clinical and neuropathological connections with these regions, [@B33] collected MRI data of 3D-T1 MR images of 49 patients with SCA3/MJD. The cortical thickness and the volume of subcortical nuclei were calculated by FreeSurfer, widespread cortical and subcortical atrophy was found ([@B33]). VBM studies also confirmed the extensive reduction in the volume of gray matter in the brain cerebral cortex, including the frontal, parietal, temporal, and occipital lobes ([@B47]; [@B30]; [@B37]). In addition, significant loss of both gray and white matter in the thalamus has been reported by VBM ([@B63]; [@B37]), which is consistent with the decreased thalamic volumes in SCA3/MJD patients when compared to controls using both automated measurements and manual segmentation methods ([@B31]).

A longitudinal study with a large number of subjects showed that the gray matter density of multiple brain regions other than the cerebellum was also a strong determinant of the final ICARS score ([@B30]), which was a strong supporting information for the widespread brain pathology in SCA3/MJD. A correlation of the atrophy profiles in the cerebellum and the brain stem with the SARA/ICARS total scores and disease duration of SCA3/MJD patients has been found ([@B79]; [@B50]; [@B104]), suggesting that these regions account for the main clinical features found in SCA3/MJD patients. In addition, a previous study using multimodal MR imaging-based analyses in a large cohort of patients and presymptomatic subjects showed that volume measurements were more sensitive than SARA ([@B110]), which provides a strong empirical basis for using these objective neuroimaging biomarkers to supplement ataxia assessment scales in the evaluation of clinical outcomes. Some neuroimaging studies have demonstrated an inverse correlation between the CAG repeats length and the volume of brainstem, cerebellum, and basal ganglia ([@B158]; [@B126]; [@B17]; [@B104]), whereas some failed to reveal a significant association between the CAG repeat expansion and the volume changes in the specific brain region ([@B16]; [@B69]; [@B39]; [@B47]; [@B49]; [@B134]; [@B54]). Apart from these neuroimaging reports, a pathoanatomic study also disclosed no correlation between the degeneration of the cerebellar Purkinje cell layer or the deep cerebellar nuclei with the CAG repeat length ([@B119]). Considering that several studies have demonstrated the inverse correlation between CAG repeat length and age of onset as well as disease severity, the rapid cerebellar degeneration in SCA3 patients with earlier disease onset may not be caused by the longer CAG repeat length alone ([@B54]).

Brain Morphology Abnormalities Progress From Infratentorial to Supratentorial Areas {#S2.SS2}
-----------------------------------------------------------------------------------

Brain morphology abnormalities are initially observed in the infratentorial areas early in the disease course. Studies in preclinical SCA3 patients have detected volumetric reductions in the brainstem, substantia nigra, and spinal cord ([@B112]). [@B58] also recorded a mild loss of brainstem volume in a cohort of nine preclinical European SCA3/MJD carriers, although the result was non-significant after a statistical analysis, which was in line with the results of a recent MRS study that demonstrated reduced N-acetyl aspartate (NAA)/myo-inositol (mI) ratios in the pons of preclinical SCA3/MJD carriers ([@B61]). These observations indicated that brain structural and functional damage begins in the early stages and precedes the onset of clinical manifestations of SCA3/MJD, which is commonly observed in neurodegenerative disorders, such as Huntington's disease, Alzheimer's disease, and familial amyotrophic lateral sclerosis ([@B108]; [@B41]; [@B77]).

Later in the disease course, structural damage diffusely proceeds to the supratentorial areas. Mild frontal atrophy and pallidal atrophy were observed in two patients whose disease durations were over 10 years ([@B141]). High-intensity change along the internal capsules was also detected by T2-weighted MR image in an autopsied case who died at aged 60, which was 19 years after her initial symptoms, and the autopsy findings suggested neuronal loss, astrocytosis, and gliosis in the internal segment of the globus pallidus ([@B53]). [@B148] detected abnormal electroencephalogram signals in the cerebral cortex of SCA3 patients in the late stage of the disease. In another study, extensive atrophy of the basal ganglia and cerebral cortex was also observed in the late stages of SCA3/MJD ([@B112]), which was consistent with the dementia and delirium symptoms in four SCA3/MJD patients in the late stages ([@B57]).

So far, the most commonly used clinical outcome and disease severity assessment measures in natural history studies and clinical trials of SCAs are ataxia rating scales such as SARA and ICARS, However, both of them are semiquantitative and lack sensitivity in the earliest stages of SCAs, including the preclinical stages when brain structural damage has already taken place ([@B112]). Although such scales are essential for disease progression assessment, they should be supplemented with quantitative and non-invasive neuroimaging data to directly assess the neuroanatomic alteration of the brain. Meanwhile, the use of MR imaging technique in the late stages of SCA3/MJD may be limited, as shown in the longitudinal study that no progression of atrophy was detected after an interval of approximately 1 year, which might be caused by the floor effect or short duration of follow-up ([@B30]). Thus, a combination of both clinical scales and MR imaging techniques or even body fluid biomarkers will allow a better reflection of the disease trajectory and a larger effect size than any biomarker alone, which will enable an accurate evaluation of disease progression and brain atrophy staging in neurodegenerative diseases, especially in rare diseases like SCA where patient recruitment is challenging. Besides that, as discovered by [@B112] a typical caudal--rostral progression of brain structural damage in SCA3/MJD patients suggested a potential staging scheme for SCA3/MJD like the Braak staging scheme of brain pathology for Parkinson's disease. Further longitudinal studies with postmortem histology data are needed to validate this hypothesis.

The Correlation of Brain Atrophy With Motor and Cognitive Impairments in SCA3/MJD Patients {#S2.SS3}
------------------------------------------------------------------------------------------

The cerebellum plays an important role not only in motor control but also in non-motor functions such as language, memory, and visual ability ([@B151]). [@B135] illustrated that when the anterior lobe of the cerebellum and parts of the cerebellum lobule VI are damaged, communication between the cerebellar motor system and the cerebral and spinal motor systems is interrupted, which can result in cerebellar motor syndrome. In addition to its role in motor coordination, the cerebellum is also involved in cognitive processing and emotional control ([@B121]). When lesions involve the posterior lobe of the cerebellum and vermis, the cerebral cognitive system modulated by the cerebellum may be disrupted, which can lead to cerebellar cognitive affective syndrome (CCAS) ([@B121]; [@B135]). Many studies have demonstrated the occurrence of cognitive deficits, including executive impairments, such as verbal fluency and verbal memory deficits, and impairments in spatial cognition, including visuospatial function, visual memory, visuoconstruction, and visual attention, and emotional deficits in SCA3/MJD patients ([@B86]; [@B160]; [@B65]; [@B67]; [@B82]; [@B115]; [@B11]), which are in accordance with the characteristic manifestations of CCAS ([@B122]; [@B120]; [@B121]; [@B11]). Widespread cerebral cortical atrophy was also correlated with motor ([@B33]) and cognitive ([@B82]) impairments. Occipital damage is specifically associated with visuospatial deficits, and the cingulate gyri plays an important role in motor control and the regulation of cognition ([@B103]; [@B33]). Atrophy of the hippocampus may partly explain the visual and verbal memory impairments observed in some SCA3/MJD patients ([@B33]).

The basal ganglia are a group of subcortical nuclei that interconnect with the thalamus and the cerebral cortex by several parallel reentrant loops and are primarily responsible for motor control ([@B4]; [@B3]). Information flows back to the cortex through two functional opposing pathways from the basal ganglia to precisely perform the movement ([@B73]). On the one hand, the motor circuit originates from several frontal lobe regions and mainly projects to the putamen. After intermediate processing, the information is returned to the neocortex through the ventrolateral part of the thalamus ([@B113]). On the other hand, the striatum can also target the output stage of the basal ganglia through the external segment of the globus pallidus and the subthalamus ([@B113]; [@B73]). Basal ganglia abnormalities can lead to dystonia and parkinsonism, however, parkinsonian motor features seem not to be that common in SCA3/MJD patients since the degeneration of the motor territory of the subthalamic nucleus can partially ameliorate the manifestation of parkinsonism in SCA3/MJD patients ([@B125]). The correlation between brain atrophy patterns and ataxia has also been found in SCA1, SCA6 ([@B126]), SCA7 ([@B51]), and SCA17 ([@B111]) patients, suggesting that these clinical manifestations may be caused by the same atrophy pattern.

However, most of the previous SCA3/MJD brain morphological studies are macroscopic changes of gray and white matter (such as the volume of gray and white matter, etc.), and the changes of brain microstructure are not very clear. In recent years, the rapid development of neuroimaging technology, especially DTI technology, provides the possibility for the study of the microstructural integrity of white matter *in vivo*.

Diffusion Tensor Imaging {#S3}
========================

Water diffuses mainly along the major axis of the white matter (WM) fiber tract in brain tissue ([@B91]). Therefore, by measuring the directionality of water diffusion (fractional anisotropy, FA) ([@B9]) and three other main parameters, including axial diffusivity (AD), radial diffusivity (RD), and mean diffusivity (MD), DTI has become a widely used quantitative and non-invasive methodology to assess the microstructure and the integrity of the brain WM fiber tracts ([@B75]). Tract-based spatial statistics (TBSS), using non-linear image transformation, is a widely applied technique in DTI analysis that can combine the strength of both voxel wise and tractography-based analyses ([@B128]). By measuring the anisotropic diffusion of water in the WM tract, TBSS can provide information about anatomical connectivity in the brain ([@B156]).

Decreased FA and Increased AD, RD, and MD in SCA3/MJD Patients {#S3.SS1}
--------------------------------------------------------------

DTI studies with TBSS have revealed a widespread decrease in FA accompanied by increased AD, RD, and MD in the WM across the whole brain, especially the cerebellum and the brainstem, as well as some supratentorial areas, such as the bilateral frontal, parietal, temporal, and occipital lobes and thalamus, in patients with SCA3/MJD compared with those in controls, as shown in [Figure 3](#F3){ref-type="fig"} ([@B49]; [@B98]; [@B59]). What is more, MD increases showed a similar pattern as FA decreases ([@B63]; [@B152]; [@B59]), and these findings were in line with the results from the multi-atlas segmented findings ([@B112]). WM abnormalities were also identified in some fiber pathways that were mostly in the cerebellar connecting tracts, including the pyramidal tract, thalamic radiations, medial lemnisci, corticospinal tract, corticobulbar tract, and corticopontocerebellar tract in patients with SCA3/MJD ([@B112]; [@B59]). WM tract impairments are common features among SCA patients. Decreased FA and increased MD in the cerebellar peduncles, the bilateral posterior limb of the internal capsule, and the corona radiata have been observed in SCA2 patients ([@B52]), and widespread FA reductions beyond the cerebellum and the pons have also been found in SCA7 patients ([@B2]).

![**(A)** Areas of reduced fractional anisotropy (*P* \< 0.05, corrected). **(B)** Areas of increased axial diffusivity (*P* \< 0.05, corrected). **(C)** Areas of increased radial diffusivity (*P* \< 0.05, corrected). Reprinted with permission from Wiley ([@B49]).](fnins-14-00749-g003){#F3}

WM Tracts Are Partially Impaired in the Preclinical Stage of SCA3/MJD {#S3.SS2}
---------------------------------------------------------------------

SCA3/MJD is a progressive neurodegeneration disease with brain pathology preceding the onset of clinical symptoms. The discovery of the microstructural changes of preclinical SCA3/MJD is helpful to find neuroimaging markers and even predict the clinical onset of disease. [@B152] identified decreased FA values and increased MD in the cerebellar peduncles of preclinical SCA3/MJD patients. A multi-atlas analysis in another study revealed that all DTI-based parameters were abnormal in the cerebellar peduncles of asymptomatic SCA3/MJD gene carriers ([@B112]). WM impairments in the cerebellum were also discovered in preclinical patients with SCA1 ([@B157]) and SCA6 ([@B40]). The cerebellar peduncles are responsible for both efferent and afferent information. The inferior cerebellar peduncles consist of olivocerebellar and dorsal spinocerebellar tracts and are mainly involved in the coordination of movement and proprioception, receiving movement information and sensory information related to movement ([@B141]). The middle cerebellar peduncles mainly receive afferent fibers from the pontine nuclei to the cerebellum, which make up most of the corticopontocerebellar tract, bringing information from the cerebral cortex ([@B66]). The superior cerebellar peduncles contain mostly efferent fibers that originate from the cerebellar nuclei for the connections of the cerebellum and the mesencephalon and the cerebrum ([@B62]; [@B32]). These abnormalities in the cerebellar peduncles in preclinical SCA patients exemplify that the afferent and efferent systems of the cerebellum have already been damaged in the early disease course of SCA.

WM Lesions Are Related to Disease Severity in SCA3/MJD Patients {#S3.SS3}
---------------------------------------------------------------

Abnormal TBSS results were inversely correlated with SARA scores, ICARS scores, and neuropsychological assessment results of SCA3/MJD patients, which indicated that damage to the WM tracts across specific regions may be closely related to disease severity in SCA3/MJD patients, including the severity of movement disorders ([@B63]; [@B104]) and cognitive dysfunction ([@B82]; [@B152]). WM plays a vital role in connecting various brain regions and coordinating the communication between them, while no significant correlation was found between any of the DTI parameters and the number of CAG repeats in expanded alleles ([@B49]; [@B63]; [@B104]).

DTI-derived AD and RD have been demonstrated to be promising biomarkers of axonal injury and myelin abnormalities, respectively, in mouse models of white matter injuries ([@B130], [@B129], [@B131]). Consistent with the DTI changes in SCA3/MJD, DTI-derived AD and RD increased were also detected in different types of multiple sclerosis lesions ([@B94]; [@B149]). It has been suspected that the changes of AD may reflect the changes of axons in a time-dependent way, characterized by initial decrease when axonal degradation is expected during the acute phase and then normalization or even increase with the removal of axonal fragments ([@B23]), while the extent of increased RD reflects the severity of demyelination and the increased freedom of cross-fiber diffusion in white matter ([@B130], [@B131]). Thus, the increase of AD and RD found in SCA3/MJD patients supports the hypothesis of the coexistence of chronic axonal damage and extensive myelin degeneration as observed in experimental models of multiple sclerosis and other white matter injuries. As previously mentioned, FA indicates the directionality of water diffusion ([@B107]), and reduced FA can be caused by the degradation of axonal membranes, i.e., myelin sheaths ([@B150]; [@B106]), and reductions in axonal fiber density ([@B137]; [@B10]). MD is the overall mean-squared displacement of water molecules restricted by organelles and membranes ([@B96]), which reflects the diffusivity of water based on cellular density and extracellular volume ([@B43]; [@B76]). Thus, reduced FA and increased MD in the same brain tissue indicate the disrupted structure of myelin and axons along with abnormal levels of cellular fluid ([@B105]). To conclude, the pattern of DTI metrics alternation in SCA3/MJD (decreased FA and increased MD, RD, and AD) reflects the dysfunction of the axonal function of white matter fibers and myelin degeneration rather than the process of primary demyelination. Neuropathological studies have observed neuronal loss and atrophy in the cerebellum, brainstem, and spinal cord ([@B114]) as well as the thalamus ([@B38]; [@B116]; [@B141]; [@B125]), basal ganglia ([@B38]; [@B154]; [@B53]), and cerebral cortex ([@B102]; [@B153]; [@B127]), which would eventually result in the loss of axons and the degeneration of neurons, providing a putative mechanism for the observed extensive WM involvement.

While it is true that DTI is very sensitive for the detection of microstructural degeneration, it is also important to note that DTI metrics such as FA or MD values can only provide comprehensive information about the integrity of brain WM ([@B22]). The sensitivity of DTI metrics to progressive brain changes in SCA3/MJD remains largely unexplored ([@B6]). In addition, the commonly used DTI model might miss a subtle degeneration in WM and fail to distinguish crossing fibers ([@B6]). These shortcomings can be compensated by more sophisticated diffusion models. Recently developed multicompartment techniques such as neurite orientation dispersion and density imaging model, by separating the signal deriving from different tissue compartments, have shown superior tissue and pathological specificity and might be particularly useful in detecting crossing fiber degeneration ([@B44]; [@B14]). It is also worth paying attention to the continuous time random walk model, which could complement the traditional DTI model by providing supplemental information of brain tissue complexity ([@B56]; [@B45]). In addition, non-Gaussian diffusion models using fractal derivative model or fractional order model have been introduced to describe anomalous diffusion in human brain tissues with improved accuracy of MR imaging ([@B85]; [@B161]; [@B80]).

Further animal studies and postmortem histology studies are still needed to validate the correlation of microstructural lesions and alteration of MRI metrics. Ideally, postmortem brain tissues are the closest ones for studying human diseases, whereas from the pre-clinical validation standpoint, animal models, especially mammalian models such as the classic ataxin-3-Q79 transgenic mouse that develops a progressive neurological phenotype of ataxia ([@B21]), the first humanized ataxin-3 knock-in mouse model, which combines the molecular and behavioral disease phenotypes with the genetic features of SCA3 ([@B136]), and other knock-in mouse model that exhibits prominent aggregate pathology ([@B109]), are all highly valuable for the clinical or the pre-clinical histopathologic validation of imaging data as well as the validation of disease mechanisms and treatment effect.

The morphological analysis of brain structure and DTI are mainly focused on the changes of brain anatomical structure at present. Although a direct and complete view of the relationship between brain structure and brain function is still largely unknown ([@B155]), the brain anatomical structure serves as the cornerstone that influences the brain function and disease progression, and the brain structural MRI researches in SCA3/MJD patients also promote the exploration of brain function.

Blood Oxygen Level-Dependent Functional MRI {#S4}
===========================================

BOLD fMRI is a commonly used technique that can detect the spatiotemporal distribution of neural activity across the brain based on the detection of blood oxygenation level-dependent signal changes ([@B99]). In general, the differences in local brain activation patterns between patients with ataxia and normal controls were analyzed, with the presumption that the existence of differences may be related to neural circuit dysfunction in the patient group ([@B26]). There is a growing interest in exploring the utility of task-based and resting-state functional MRI in SCA patients for monitoring functional abnormalities in brain tissue.

Functional MRI patterns have detected a general dysfunction in the motor network in SCA3/MJD patients. [@B134] found that hand movement-related cerebellar activation was altered in SCA3/MJD patients, and significant activation in the ventral part of the dentate nucleus along with a reduced but non-significant reduction in the cerebellar cortex was detected when the subjects were instructed to open and close their right fist at a frequency of 1.66 Hz. Interestingly, in another fMRI study, cortical region activation was increased at 1 and 3 Hz but decreased at 5 Hz in 13 patients with early SCA3/MJD who were instructed to finger tap at 1, 3, and 5 Hz. Additionally, significant activation of subcortical regions, including the putamen, globus pallidus, and thalamus, was also discovered ([@B37]).

The activation of cortical and subcortical regions in SCA3/MJD patients might represent a compensatory mechanism to overcome cerebellar dysfunction. Variations in BOLD fMRI signals depend on synaptic input ([@B74]). Given that the ventral dentate nucleus is included in the pontocerebellar pathway ([@B46]), the increased activation of the ventral part of the dentate may suggest a possible compensatory recruitment of pontocerebellar areas to compensate for dysfunction in the spinocerebellar projections ([@B134]), which is consistent with immunohistochemical data showing that afferent mossy fibers from pontine nuclei were preserved in SCA3/MJD patients ([@B70]). The decreases in the fMRI signal in SCA3/MJD patients may be due to decreased mossy fiber input to the cerebellum caused by the degeneration of the spinocerebellar tract. In addition, decreased activation at high frequency may hint that patients had surpassed the dynamic range of maintained function ([@B37]). However, BOLD fMRI studies in patients with SCA3/MJD are very limited, and further studies are required to validate these hypotheses.

This inconsistency between the two studies may have been caused by differences in movement postures and frequency variation. In addition, discrepancies in the clinical characteristics of the patients studied, such as course of disease, CAG copy number, SARA scores, etc., may have also affected the results. Therefore, further prospective studies are needed to address the sensitivity and the specificity of these findings.

Magnetic Resonance Spectroscopy {#S5}
===============================

MRS is a non-invasive method that allows *in vivo* quantification of altered metabolite concentrations in brain tissue based on signals of hydrogen protons. MRS can provide biomarkers for neurological disorders even in cases where a lesion has not yet been observed in MR images ([@B36]). The levels of NAA, Cho, mI, and Cr are the main metabolites that are focused on in most MRS studies. NAA concentration is an indicator of neuronal volume, viability, and integrity ([@B7]; [@B143]), and the lack of NAA is associated with injury or loss of neurons and axons in various conditions ([@B15]; [@B72]; [@B89]; [@B100]). Cho is the precursor of the neurotransmitter acetylcholine and membrane constituent phosphatidylcholine ([@B90]) and serves as an indicator of cell membrane and neurotransmitter metabolism ([@B81]), mI is a marker of glial activation ([@B12]), which reflects neuronal injury and degeneration ([@B36]), and Cr is an indicator of brain energy metabolism ([@B42]; [@B81]). The concentration of Cr is relatively stable under normal conditions; therefore, it often serves as a reference for comparisons ([@B81]). Each metabolite shows a characteristic pattern at very specific resonance frequencies in MRS ([@B25]). The neurometabolic spectrum detected in patients reflects the cell-specific changes in neurons or astrocytes, which cannot be evaluated by other neuroimaging methods.

Neurochemical Alterations in Clinical SCA3/MJD Patients {#S5.SS1}
-------------------------------------------------------

Lower NAA and glutamate levels, reflecting the loss or dysfunction of neurons, were detected in the cerebellum and pons of SCA3/MJD patients ([@B1]), which was in agreement with the neuron loss found by neuropathological and structural imaging studies ([@B141]; [@B83]; [@B49]). The glial marker mI was elevated in the cerebellum and pons ([@B1]), reflecting the activation of glial cells in response to neuron degeneration ([@B12]; [@B5]; [@B36]). Total Cr (tCr) levels were also elevated in both the cerebellar vermis and pons in SCA3/MJD patients ([@B1]). The increase in tCr may be a compensatory response to maintain the function of the phosphocreatine/creatine kinase system to ensure the energy supply of brain tissue ([@B13]). Moreover, the increased tCr may play a role in inhibiting the formation of free radicals and thereby strengthen neuroprotection ([@B1]). Similarly, increased tCr has also been detected in the brains of Huntington's disease mouse models by 1H MRS ([@B159]), suggesting that there may be similar abnormalities in brain energy metabolism in polyglutamine disease. Additionally, there is also evidence that the levels of glutamate and glutamine were reduced in cerebellar lesions, reflecting neuronal loss/dysfunction ([@B82]; [@B1]).

In line with previous findings of decreased NAA/Cr ratios in the cerebellum ([@B81]; [@B146]; [@B82]; [@B18]; [@B54]; [@B104]) and deep WM ([@B27]), a recent meta-analysis has also demonstrated a decrease in the NAA/Cr ratio in the cerebellum of SCA3/MJD patients compared to that of normal controls ([@B71]). Reduced NAA/Cho, a marker reflecting brain metabolism ([@B89]; [@B97]; [@B145]), was also observed in the same areas ([@B81]; [@B18]; [@B104]). Therefore, levels of NAA, suggestive of extensive neuronal and axonal dysfunction, might be regarded as an effective diagnostic marker of neurodegeneration in SCA3/MJD. The patterns with Cho/Cr have been more heterogeneous, with some studies demonstrating a reduced Cho/Cr ratio in the cerebellum ([@B104]; [@B71]), but this was not obvious in other studies ([@B146]; [@B18]). Regarding these findings, further studies are needed to validate Cho as a metabolic marker ([@B71]). The abnormal neurochemical ratios in different brain regions are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Abnormal neurochemical ratios in different brain regions.

  Brain region        Abnormal neurochemical ratios   References
  ------------------- ------------------------------- ------------------------------------------------------------------
  Cerebellum          NAA/Cr                          [@B78]; [@B81]; [@B146]; [@B82]; [@B18]; [@B54]; [@B104]; [@B71]
                      Cho/Cr                          [@B104]; [@B71]
                      NAA/mI                          [@B61]
                      NAA/Cho                         [@B78]; [@B81]; [@B18]; [@B104]
  Brain stem          NAA/mI                          [@B61]
  Thalamus            NAA/Cr, NAA/Cho                 [@B104]
  Deep white matter   NAA/Cr, Cho/Cr                  [@B27]

Neurochemical Profile Abnormalities Precede Clinical Manifestations {#S5.SS2}
-------------------------------------------------------------------

A recent profound study detected reduced NAA/mI ratios in the pons and cerebellum in SCA3/MJD patients whose estimated disease onset was within 10 years ([@B61]). Significantly reduced NAA/Cr and NAA/Cho ratios in the cerebellar hemispheres and vermis were also observed in the early stages of SCA3/MJD (SARA score \< 10) ([@B81]). Using 18F-fluorodeoxyglucose positron emission tomography, Soong and Liu detected abnormal FDG consumption levels in the cerebellum, brainstem, and cerebral cortex in asymptomatic carriers of SCA3/MJD ([@B132]). Additionally, in other SCA diseases, such as SCA1, SCA2, and SCA6, neurochemical changes were also found to precede the onset of clinical manifestations ([@B48]; [@B146]). Potentially, MRS can reveal early metabolic/cellular changes in various SCAs, which are likely to occur before cerebellar signs are obvious, even before brain atrophy, which indicates that the measurement of neurochemical changes in brain tissue by MRS may be superior to clinical observation in particular circumstances. The discovery of early neurochemical changes in non-ataxia mutant gene carriers could not only help to illustrate the underlying pathophysiology of SCAs but also provide a window for early intervention preceding irreversible brain damage. However, neurochemical abnormalities in the premanifest stage of SCAs remain largely unexplored ([@B61]). More studies at the preclinical stage in patients with different SCA genotypes are needed to further support the potential of neurochemical metabolites as prognostic biomarkers.

Neurochemical Metabolites Are Associated With Clinical Features {#S5.SS3}
---------------------------------------------------------------

Similar to morphometric neuroimaging, neurochemical alterations, including NAA/Cr, Cho/Cr, or NAA/Cho ratios, correlated with disease duration, SARA scores ([@B81]; [@B146]; [@B54]), ICARS scores ([@B104]), and genetic data ([@B146]; [@B104]) in SCA3/MJD patients, suggesting that MRS can serve as a biomarker to monitor the progression of ataxia and evaluate the response to therapeutic interventions, even in the early stages of SCA3. Importantly, an animal study of SCA1 has validated the sensitivity and the specificity of MRS as a non-invasive technique to reflect the extent of recovery from neurodegeneration even better than standard motor behavioral assessment ([@B101]). Moreover, the test--retest reproducibility of neurochemical profiles by MRS was demonstrated to be reliable not only within site ([@B139]) but also between sites ([@B34]; [@B144]), which is crucial for its utility in future multisite trials. However, there have also been contrasting findings that make these inferences inconclusive; these studies showed that CAG repeat length and clinical features (such as SARA scores and course of disease) were not related to the concentrations of any neurochemical metabolites ([@B27]; [@B1]; [@B61]). The detailed correlations of neurochemical ratio abnormalities and clinical data are summarized in [Table 3](#T3){ref-type="table"}. A recent study using a novel multi-variate approach, distance-weighted discrimination, allows a combination of multiregional neurochemical profiles to estimate time to disease onset, and the correlation between the DWD-based MRS scores and SARA and duration in SCA3 patients has suggested a regional effect of neurochemical profiles ([@B61]). Further studies would be of interest to determine whether neurochemical metabolite levels are a useful biomarker of disease progression, and the relationship between regional neurochemical levels and brain pathology deserves more attention.

###### 

The correlation of neurochemical ratio abnormalities and clinical data.

  Clinical data   Correlation   Cerebellum        Deep white matter                      
  --------------- ------------- ----------------- ------------------- --------- -------- --------
  DD              Relevant      [@B54]; [@B104]   [@B104]             [@B81]    /        /
                  Irrelevant    [@B81]            [@B81]              [@B104]   [@B27]   [@B27]
  SARA            Relevant      [@B81]; [@B146]   [@B81]              [@B81]    /        /
                  Irrelevant    /                 /                   /         /        /
  ICARS           Relevant      [@B104]           [@B104]             /         /        /
                  Irrelevant    /                 /                   [@B104]   [@B27]   [@B27]
  CAG             Relevant      [@B104]           /                   [@B104]            
                  Irrelevant    [@B146]; [@B54]   /                   /         [@B27]   [@B27]

DD, disease duration.

Conclusion and Perspectives {#S6}
===========================

In conclusion, this review summarized the value of MR imaging techniques in detecting structural and functional changes in patients with SCA3/MJD and demonstrated the feasibility of detecting neuroimaging abnormalities in the preclinical stage of this disease, as well as their correlations with clinical features and disease severity. These MR imaging abnormalities identified in clinical and preclinical SCA3/MJD patients provide significant insights into the pathogenesis of the disease. Morphometric MR imaging has been proven to be an effective method of monitoring brain atrophy. DTI studies provide comprehensive information about the integrity of brain WM, and metabolites related to neuronal loss, glial cell activation, and abnormal brain energy metabolism have been detected by MRS. Both DTI and MRS abnormalities indicate that the synaptic function or density might have been disrupted, while the sensitivity of DTI metrics, MRS, and functional MR imaging alterations to progressive changes of brain tissue in SCA3/MJD remains unclear. In addition, due to the heterogeneity in imaging parameters across different studies, such as the magnetic flux density, sequences of image acquisition, and operation protocols, the accuracy of a direct comparison between various research results is relatively limited. Histopathologic and animal studies are further needed to validate the correlation between MR imaging and pathological findings. A combination of multiple data sets from magnetic resonance imaging and clinical scales or even body fluid biomarker might perform better in the identification of potential biomarkers in SCAs. Validated neuroimaging biomarkers are of great value in guiding patient eligibility, patient stratification, and tracking therapeutic response in clinical trials. Standardized and systematic analyses of demographics and clinical and genetic data could contribute to defining the sensitivity of neuroimaging biomarkers. In light of this fact, multisite longitudinal prospective studies utilizing multimodal MR imaging techniques in a large cohort of patients as well as preclinical mutation carriers with SCA3/MJD are crucially needed to validate the capability of MR imaging in the diagnosis and the differentiation of SCA subtypes, predicting the age of disease onset in preclinical individuals, monitoring disease progression even before the onset of symptoms, and assessing the therapeutic effect of clinical treatments.
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